KYMR
Kymera Therapeutics, Inc. Common StockData: 2026-10-22
Quick Stats
Oct 22, 202657.9
AI Score
HOLD1.01
Volume Ratio
Nov 03, 2026
Next Earnings
14
+ve Days (30d)
16
-ve Days (30d)
KYMR Price vs Max Options Open Interest
How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.
KYMR Max Change In Options Open Interest
How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.
KYMR Options - Sort by Max open Interest (near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KYMR Daily Out of Money Options - Sort by Max open Interest (near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KYMR Daily In the Money Options - Sort by Max open Interest (near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KYMR Most Active Options by Volume(near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KYMR Technical Chart Pro Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Volume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
KYMR Stock Summary
Last updated Oct 22, 2026
KYMR is currently trading at $110.85, positioned above its 200-day moving average of $95.09, indicating a long-term uptrend. The stock has a 52-week range of $55.2601 to $130.05.
Technical Analysis: The 50-day moving average stands at $115.09, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 49.197, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.06, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates KYMR at 57.9/100 with a HOLD recommendation.
KYMR (Kymera Therapeutics, Inc. Common Stock) Indicators
Last updated Oct 22, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 49.197 |
| CMF (20) | -0.06 |
| ROC (10) | 1.418 |
| ADX (14) | 11.096 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -1.045 |
| AROONOSC (14) | 21.429 |
| WILLAMS %R (14) | -35.288 |
| MFI (14) | 60.613 |
KYMR Candlestick Patterns
Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.
| Date | Pattern | Signal | 5-Day Hit Rate | Edge vs Baseline | Sample |
|---|---|---|---|---|---|
| Oct 16 | Marubozu (bearish) (contrarian — textbook says the opposite) | Bullish | 56.2% | +3.2 pts | 30540 |
| Oct 14 | On-Neck | Bearish | 49.1% | +2.1 pts | 3813 |
| Oct 13 | Three Inside Down (contrarian — textbook says the opposite) | Bullish | 56.9% | +3.9 pts | 8868 |
These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.
Kymera Therapeutics, Inc. Common Stock is above the 200 Day SMA but below the 50 Day SMA — long-term uptrend intact but under near-term pressure (Mixed).
KYMR Moving Averages Analysis
Kymera Therapeutics, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Oct 22, 2026
KYMR (Kymera Therapeutics, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Oct 22, 2026
| Days | MA |
|---|---|
| 10 | 109.59 |
| 20 | 109.66 |
| 30 | 111.98 |
| 50 | 115.09 |
| 100 | 108.7 |
| 200 | 95.09 |
KYMR Fundamental Analysis
| P/E (Forward) | -- |
| P/E (Trailing) | -- |
| Market Cap ($) | 9.3 billion |
| Earnings/Share ($) | -3.25 |
| Net Profit Margin (%) | -2.8533 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -3.8504 |
| EPS Estimate Next Year ($) | -5.0974 |
| WallStreet Target Price ($) | 139.35 |
| Most Recent Quarter |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.